Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus vaccine H1N1 - GSK

Next Previous
Drug Profile

Influenza A virus vaccine H1N1 - GSK

Alternative Names: Arepanrix H1N1; GSK 2340272A; GSK 2340273A; GSK 2340274A; GSK 234072A; H1N1 pandemic influenza virus vaccine - GSK; Influenza A H1N1 split virion vaccine - GSK; Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) - GSK; Pandemrix; Pandemrix H1N1; Swine flu vaccine - GSK; Unadjuvanted influenza A (H1N1) vaccine - GSK

Latest Information Update: 02 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK; Japan Vaccine
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 02 Aug 2019 Influenza A virus vaccine H1N1 is not yet available for Influenza A virus H1N1 subtype (Prevention) in USA, JApan (IM)
  • 20 Mar 2015 The vaccine is approved in USA, and is in phase-III development in Latin America and Asia
  • 22 Jul 2011 EMA's Committee for Medicinal Products for Human Use completes its review of Pandemrix and the risk of narcolepsy in subjects aged less than 20 years, and recommends the agent only be used in such subjects when the recommended seasonal trivalent influenza vaccine in unavailable and immunisation is still required
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top